---
title: "Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of \"Hold\" from Brokerages"
description: "Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of \"Hold\" from nine brokerages, with five analysts recommending a hold and four a buy. The average 12-month target price is"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/244827493.md"
published_at: "2025-06-17T05:33:05.000Z"
---

# Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

> Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of "Hold" from nine brokerages, with five analysts recommending a hold and four a buy. The average 12-month target price is $8.24. The stock opened at $1.51, with a 12-month low of $1.01 and a high of $8.87. Recently, Director Scott Dunseth Myers purchased 21,000 shares at $1.40 each. Institutional investors have also been active, with several acquiring new stakes in the company.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given a consensus rating of "Hold" by the nine brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.24.

A number of equities analysts have recently commented on ZNTL shares. Wedbush restated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th.

**View Our Latest Stock Analysis on ZNTL**

## Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $1.51 on Tuesday. The stock's 50-day moving average is $1.33 and its 200-day moving average is $2.00. The company has a market cap of $108.65 million, a price-to-earnings ratio of -0.61 and a beta of 1.61. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $8.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). Research analysts anticipate that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

## Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by company insiders.

## Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $72,000. Ieq Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $46,000. Anfield Capital Management LLC grew its position in shares of Zentalis Pharmaceuticals by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company's stock worth $392,000 after acquiring an additional 64,659 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Zentalis Pharmaceuticals by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock worth $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $68,000.

## About Zentalis Pharmaceuticals

(Get Free Report

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

## Featured Stories

-   Five stocks we like better than Zentalis Pharmaceuticals
-   Short Selling - The Pros and Cons
-   New Catalysts to Drive NVIDIA’s Stock Price Even Higher
-   How to Use High Beta Stocks to Maximize Your Investing Profits
-   China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
-   What Are Growth Stocks and Investing in Them
-   Palantir Defies Bears, Leads S&P 500 in 2025

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Zentalis Pharmaceuticals Right Now?

Before you consider Zentalis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.

While Zentalis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [ZNTL.US - ZeZentalis Pharma](https://longbridge.com/en/quote/ZNTL.US.md)
- [BMY.US - Bristol Myers Squibb](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股异动速递：地产股领涨，Wheeler Real Estate 涨超 31%，生物科技股普跌 | 美股市场概况在过去的一小时内，美股市场呈现出显著的板块轮动特征，房地产和科技板块表现尤为突出。Wheeler Real Estate 领涨，带动了房地产板块的整体上扬，而科技股中，Fathom 和 Icon Energy 的强势表现也引发了 | [Link](https://longbridge.com/en/news/272020551.md) |
| 主要投资者对 ZeZentalis Pharmaceuticals 股票采取了大胆举措 | Zentalis Pharmaceuticals (ZNTL) 在 2026 年 1 月 8 日出现了显著的内部交易活动，WALTERS GROUP 通过购买 6,459,973 股股票增加了其持股，交易金额为 775 万美元，这表明投资者 | [Link](https://longbridge.com/en/news/272013593.md) |
| 美股异动速递：Wheeler Real Estate 涨 24.59%，3D 系统涨 16.80%，flyExclusive 跌 13.55% | 美股近一小时市场概况美股市场在近一小时内呈现出明显的板块轮动现象，房地产和科技板块表现尤为突出。资金流向集中在小盘股和题材股，市场情绪较为活跃。整体来看，涨幅较大的股票主要集中在房地产和医药板块，而科技股也有不俗表现。短线资金的快速流动使得 | [Link](https://longbridge.com/en/news/272040574.md) |
| 美股异动速递：ZeZentalis Pharma 领涨 33%，flyExclusive 跌近 14% | 美股市场概况在过去的一小时内，美股市场呈现出明显的板块轮动特征，医药和房地产板块表现尤为突出。资金流向显示出对小盘股和题材股的偏好，尤其是医药类股的强劲表现引人注目。市场情绪活跃，波动幅度较大，短线热度持续上升。近一小时异动最大股票 ZeZ | [Link](https://longbridge.com/en/news/272048606.md) |
| 美股异动速递：生物医药板块走强，Abivax SA 涨 21.95%，Alpha Tech 跌 11.07% | 美股市场概况在过去的一小时内，美股市场呈现出明显的板块轮动特征，尤其是医药和生物科技板块表现突出。资金流入小盘股和题材股，推动了短线热度的上升。市场情绪偏向积极，波动幅度较大，显示出投资者对特定领域的强烈兴趣。近一小时异动最大股票 Abiv | [Link](https://longbridge.com/en/news/272227875.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
